Arvanil, anandamide and N‐arachidonoyl‐dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Cannabinoid (CB) agonists suppress nausea and vomiting (emesis). Similarly, transient receptor potential vanilloid‐1 (TRPV1) receptor agonists are anti‐emetic. Arvanil, N‐(3‐methoxy‐4‐hydroxy‐benzyl)‐arachidonamide, is a synthetic ‘hybrid’ agonist of CB 1 and TRPV1 receptors. Anandamide and N‐arachidonoyl‐dopamine (NADA) are endogenous agonists at both these receptors. We investigated if arvanil, NADA and anandamide were anti‐emetic in the ferret and their mechanism of action. All compounds reduced the episodes of emesis in response to morphine 6 glucuronide. These effects were attenuated by AM251, a CB 1 antagonist that was pro‐emetic per se, and TRPV1 antagonists iodoresiniferatoxin and AMG 9810, which were without pro‐emetic effects. Similar sensitivity to arvanil and NADA was found for prodromal signs of emesis. We analysed the distribution of TRPV1 receptors in the ferret brainstem and, for comparison, the co‐localization of CB 1 and TRPV1 receptors in the mouse brainstem. TRPV1 immunoreactivity was largely restricted to the nucleus of the solitary tract of the ferret, with faint labeling in the dorsal motor nucleus of the vagus and sparse distribution in the area postrema. A similar distribution of TRPV1, and its extensive co‐localization with CB 1, was observed in the mouse. Our findings suggest that CB 1 and TRPV1 receptors in the brainstem play a major role in the control of emesis by agonists of these two receptors. While there appears to be an endogenous ‘tone’ of CB 1 receptors inhibiting emesis, this does not seem to be the case for TRPV1 receptors, indicating that endogenously released endocannabinoids/endovanilloids inhibit emesis preferentially via CB 1 receptors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mechoulam, R., Ben-Shabat, S., Hanus, L., Ligumsky, M., Kaminski, N. E., Schatz, A. R., Gopher, A., Almog, S., Martin, B. R., Compton, D. R., et al. (1995) · Biochemical Pharmacology · doi:10.1016/0006-2952(95)00109-d · Cited by 2,913 · cited 1×
“…1992) and N-arachidonoyl-dopamine (NADA; Huang et al., 2002) have been shown to activate both receptor types, whereas 2-arachidonoylglycerol (2-AG, Mechoulam et al., 1995; Sugiura et al., 1995) and 12-hydroperoxy-eicosatetraenoic acid (Hwang et al., 2000) or N-oleoyldopamine (Chu et al., 2003)…”
Background2-Arachidonoylgylcerol: A Possible Endogenous Cannabinoid Receptor Ligand in Brain
Sugiura, T., Kondo, S., Sukagawa, A., Nakane, S., Shinoda, A., Itoh, K., Yamashita, A., & Waku, K. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.2437 · Cited by 2,196
Identification and Functional Characterization of Brainstem Cannabinoid CB2Receptors
Van Sickle, M. D., Duncan, M., Kingsley, P. J., Mouihate, A., Urbani, P., Mackie, K., Stella, N., Makriyannis, A., Piomelli, D., Davison, J. S., et al. (2005) · Science · doi:10.1126/science.1115740 · Cited by 1,470
Self-citationModulation of anxiety through blockade of anandamide hydrolysis
Kathuria, S., Gaetani, S., Fegley, D., Valiño, F., Duranti, A., Tontini, A., Mor, M., Tarzia, G., Rana, G. L., Calignano, A., et al. (2003) · Nature Medicine · doi:10.1038/nm803 · Cited by 1,293 · cited 3×
“In the next study, the endocannabinoid reuptake inhibitor, VDM11 (2 mg ⁄ kg, De Petrocellis et al., 2000; Tocris) and the inhibitor of anandamide hydrolysis, URB597 (5 mg ⁄ kg, Kathuria et al., 2003; Axorra) were administered 15 min before M6G.”
BackgroundMethodDe Petrocellis, L., Bisogno, T., Davis, J. B., Pertwee, R. G., & Di Marzo, V. (2000) · FEBS Letters · doi:10.1016/s0014-5793(00)02082-2 · Cited by 347
Melck, D., Bisogno, T., De Petrocellis, L., Chuang, H.-H., Julius, D., Bifulco, M., & Di Marzo, V. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1105 · Cited by 188
Cited by
Targeting the endocannabinoid system: to enhance or reduce?
Di Marzo, V. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2553 · Cited by 798
Self-citationCannabinoids and the gut: New developments and emerging concepts
Izzo, A. A., & Sharkey, K. A. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2009.12.005 · Cited by 419
Self-citationPathophysiological and neurochemical mechanisms of postoperative nausea and vomiting
Horn, C. C., Wallisch, W. J., Homanics, G. E., & Williams, J. P. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.10.037 · Cited by 288
Fraguas-Sánchez, A. I., & Torres-Suárez, A. I. (2018) · Drugs · doi:10.1007/s40265-018-0996-1 · Cited by 271
Regulation of nausea and vomiting by cannabinoids
Parker, L. A., Rock, E. M., & Limebeer, C. L. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01176.x · Cited by 268
Metadata
- Authors
- Sharkey, K. A., Cristino, L., Oland, L. D., Van Sickle, M. D., Starowicz, K., Pittman, Q. J., Guglielmotti, V., Davison, J. S., & Di Marzo, V.
- Venue
- European Journal of Neuroscience
- Publisher
- Wiley
- Published
- 2007-05
- Volume
- 25
- Issue
- 9
- Pages
- 2773-2782
- ISSN
- 0953-816X (ISSN-L)
- 1460-9568
- OpenAlex
- W1824181778
- Cited by
- 120
- References
- 6
- FWCI
- 8.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Arvanil, anandamide and N‐arachidonoyl‐dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret. https://app.cochat.ai/papers/10.1111/j.1460-9568.2007.05521.x
- The paper
- Sharkey, K. A., Cristino, L., Oland, L. D., Van Sickle, M. D., Starowicz, K., Pittman, Q. J., Guglielmotti, V., Davison, J. S., & Di Marzo, V. (2007). Arvanil, anandamide and N‐arachidonoyl‐dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret. European Journal of Neuroscience. https://doi.org/10.1111/j.1460-9568.2007.05521.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.